| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Research Abstract |
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) shows good clinical outcome in lung adenocarcinoma patients harboring activating EGFR mutations, but most of them acquire resistance. Investigation of mechanisms of acquired resistance and establishment of new treatment strategy are extremely needed. We performed microarray of miRNAs in acquired resistant cell lines as well as parental cell lines and elucidated miR-200 as a candidate of TKI-resistance related miRNA. We also analyzed the effect of Tae226, an inhibitor for FAK, to find that TAE226 showed significant anti proliferative effect on EGFR-mutant lung cancer with or without TKI resistance in vitro and in vivo.
|
